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Endovascular treatment of common femoral
artery obstructions
Frederic Baumann, MD,a Mirka Ruch,a Torsten Willenberg, MD,a Florian Dick, MD,b Dai-Do Do, MD,a
Hak-Hong Keo, MD,a Iris Baumgartner, MD,a and Nicolas Diehm, MD,a Berne, Switzerland
Objective: To evaluate the clinical efficacy of endovascular therapy of symptomatic obstructions of the common femoral
artery (CFA).
Methods: Consecutive series of patients undergoing endovascular therapy of chronic CFA obstructions between 1995 and
2009 and who were followed systematically within a prospectively maintained database. Clinical assessment was based on
current guidelines including ankle-brachial index (ABI) and was performed at baseline and the day of discharge and then
repeated at 3, 6, and 12 months and annually thereafter. Technical success of intervention was defined as a final residual
diameter stenosis of<30%. Sustained clinical improvement was defined as a sustained upward shift of at least one category
on the Rutherford classification compared with baseline without the need for repeated target lesion revascularization
(TLR) or amputation in surviving patients. Limb salvage was defined as absence of a major (ie, above the ankle)
amputation. Survival analysis was performed using the Kaplan-Meier method.
Results:Ninety-eight patients (38 women, mean age 72 11 years) presented with 104 ischemic limbs, 20 of which (19%)
were classified as having critical limb ischemia (CLI). Technical success rate was 98%. Stents were placed in eight CLI
patients (40%) and in 20 claudicants (24%). Mean ABI improved from 0.28 to 0.54 (P< .001) in CLI patients and from
0.61 to 0.85 (P < .001) in claudicants. Mean follow-up was 16 months. Primary sustained clinical improvement rates at
3, 6, 12, and 24 months were 55%, 55%, 40%, and 0% in CLI patients and 81%, 75%, 68%, and 52% in claudicants,
respectively. Limb salvage rates at 24 months were 94% in CLI patients and 100% in claudicants. After adjustment for
confounding factors, presence of ischemic ulcers (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.49-14.85; P
.009), obstruction of the femoropopliteal arterial tract (HR, 3.9; 95% CI, 1.66-9.16; P  .002) and diabetes mellitus
(HR, 2.3; 95% CI, 1.02-5.28; P  .045) were independently associated with lower rates of sustained clinical
improvement.
Conclusions: Endovascular therapy of CFA obstruction is associated with high rates of sustained clinical success in
claudicants with patent femoropopliteal outflow. Presence of ischemic skin ulcers and diabetes mellitus, however, are
associated with impaired efficacy of endovascular CFA treatment. (J Vasc Surg 2011;53:1000-6.)
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cFor over 50 years, surgical endarterectomy has been
considered themajor treatment option for patients present-
ing with claudication or critical limb ischemia (CLI) due to
arterial obstruction at the level of the common femoral
artery (CFA) or the femoral bifurcation.1-6 Associated pri-
mary patency rates are reported to be as high as 96% up to
7 years;4 however, major complications such as infections,
hematoma, seroma, and lymphatic leaks may occur in up to
17.1%7 of cases.
Endovascular therapy has emerged as the first-line
treatment option for most patients with claudication and
CLI and has gained widespread acceptance among vascular
physicians and patients due to its minimally invasive char-
acter.8 However, to date, studies reporting clinical out-
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1000omes after endovascular CFA revascularization are limited
o case reports9,10 or anecdotal experience.3,11,12 Thus, the
im of the present study was to scrutinize the clinical
fficacy of endovascular therapy for CFA obstructions and
hose involving the femoral artery bifurcation in a prospec-
ively followed, consecutive patient cohort.
ATIENTS AND METHODS
This is a post hoc analysis of data derived from a
rospectively maintained database of all patients undergo-
ng endovascular therapy for chronic obstruction at the
FA level between 1995 and 2009 in a tertiary referral
enter responsible for a population of about one million.
All patients were evaluated by a multidisciplinary vas-
ular board including interventional angiologists, vascular
urgeons, and radiologists.13 Since thrombendarterectomy
as considered the gold standard for CFA obstructions
uring the study period, endovascular therapy was per-
ormed only in case of high comorbidity, patients’ refusal to
ndergo open surgery, or in case of CFA restenosis after
hrombendarterectomy.
Ethics committee approval was waived since patients
ere treated on a regular clinical basis. The study was
arried out according to the Declaration of Helsinki,14 and
onsent forms were obtained from all patients prior to
nclusion into the prospective database.
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Volume 53, Number 4 Baumann et al 1001CLI was defined according to the Second European
Consensus Document15 as persistently recurring ischemic
rest pain requiring analgesia for more than 2 weeks or
ulceration or gangrene of the foot or the toe associated with
an ankle systolic pressure50mmHg and/or a toe systolic
pressure of 30 mm Hg. All patients were evaluated using
ankle and toe pressure measurement.
Assessed risk factors included patient age and gender,
hyperlipidemia, diabetes mellitus, arterial hypertension,
coronary heart disease, renal insufficiency, cerebrovascular
disease, and cigarette smoking (Table I) as defined else-
where.16
Endovascular procedures. Lesions were treated pri-
marily by percutaneous transluminal angioplasty (PTA).
Inflation time was 2 minutes and pressures ranged from 8
to 12 atmospheres. In case of suboptimal angiographic
results, repeated inflations were performed at the discretion
of the interventionalist. Additional stenting was performed
at the discretion of the interventionalist in case of a residual
stenosis 30%16 after PTA.
We assessed arterial in- (common or external iliac ar-
tery) and outflow (deep or superficial femoral and popliteal
arteries) on the basis of procedural digital subtraction an-
giography. An obstructive lesion was defined as diameter
reduction 50%.17 Patency of the infrageniculate arteries
was assessed at baseline and graded as 1, 2, or 3 (number of
patent runoff vessel). In- or outflow obstructions were
treated by endovascular means in the same session as CFA
angioplasty.
Patient follow-up. Postprocedural assessments were
performed at the day of discharge and after 3, 6, and 12
months and annually thereafter. Patients were advised to
contact the outpatient clinic at the onset of new or wors-
ening symptoms. Follow-up of all patients included clinical
examination and assessment of symptoms according to
Rutherford classification17,18 as well as oscillometric
workup and measurement of ankle-brachial index (ABI).19
Duplex ultrasound of the target limb arteries was per-
formed in cases of recurrent symptoms or hemodynamic
deterioration.16
Endpoint definitions. Complications and endpoint
definitions were in line with current study guidelines.16,17
Table I. Demographic and risk factor data of 98 patients u
obstructions
Total cohort (n  98)
Age, years (SD) 72 (11)
Men, n (%) 60 (61%)
Hyperlipidemia, n (%) 69 (70%)
Creatinine, mean (mol/L), (SD) 97.8 (65.3)
Coronary heart disease, n (%) 42 (43%)
Cerebrovascular disease, n (%) 9 (9%)
Arterial hypertension, n (%) 78 (80%)
Diabetes mellitus, n (%) 32 (33%)
Smoking, n (%) 61 (69%)
CLI, Critical limb ischemia; SD, standard deviation.Technical success was defined as successful deployment of phe device with a residual diameter reduction of 30% on
he procedural completion angiogram in at least two differ-
nt projections.
Primary sustained clinical improvement in claudicants
as defined as sustained upward shift of at least one cate-
ory on the Rutherford classification compared with base-
ine without repeated target lesion revascularization (TLR)
f the initially treated CFA lesion or amputation in surviv-
ng patients (ie, dead patients were censored at the time
oint when they were last examined). Accordingly, a sus-
ained upward shift on Rutherford classification to at least a
evel of claudication was mandated in CLI patients. Sec-
ndary sustained clinical improvement was defined accord-
ngly including repeated TLR of the initially treated CFA
esion. Conversely, clinical deterioration was defined as a
owngrade of 1 category on the Rutherford scale after
he endovascular treatment.
TLR was defined as any repeated procedure (endovas-
ular or surgical) for a problem arising from the initially
reated CFA lesion (1 cm proximally or distally to include
dge phenomena). Target extremity revascularization (TER)
as defined as any repeated revascularization procedure
endovascular or surgical) for a problem arising remotely
rom the initially treated CFA lesion to capture progression
f clinically significant atherosclerosis.
Hemodynamic improvement was defined as an imme-
iate ABI improvement of 0.1 or to an ABI 0.9 post-
rocedurally compared with baseline. To assess hemody-
amic outcomes of CFA angioplasty in patients undergoing
ultilevel revascularization, patients were grouped as fol-
ows: Iliac plus CFA revascularization, CFA plus femoro-
opliteal and below-the-knee revascularization, CFA plus
eep femoral artery revascularization, and isolated CFA
evascularization.
Sustained hemodynamic improvement was defined ac-
ordingly. Major (ie, above the ankle) and minor (ie, below
he ankle) amputation rates were reported separately.
eriprocedural mortality was defined as deaths from any
ause within 30 days of the intervention.
Statistical analyses. Statistical analysis was performed
sing the MedCalc Software (MedCalc Software, Version
1.2.1, Mariakerke, Belgium). Categorical variables are
rgoing endovascular treatment of common femoral artery
CLI (n  20) Claudication (n  78) P value
77 (10) 70 (11) .01
8 (40%) 52 (67%) .04
10 (50%) 59 (76%) .03
121.9 (134.1) 92.0 (31.7) .001
9 (45%) 33 (42%) 1.0
4 (20%) 5 (6%) .08
16 (80%) 62 (79%) 1.0
7 (35%) 25 (32%) .79
14 (70%) 47 (60%) .61nderesented as numbers and percentages, and differences
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April 20111002 Baumann et alwere assessed by the Fisher exact test. Continuous and
normally distributed variables are reported as means 
standard deviation (SD) and as medians and interquartile
ranges and differences were assessed by the independent
samples t test.
Cumulative analysis of endpoints was assessed using
Kaplan-Meier curves.20 For estimates of cumulative mor-
tality, patients were uncensored in case of death; for all
other analysis, limbs were uncensored in case of minor or
major amputation, repeated TLR, and whenever clinical
improvement was either never reached or lost. Patients at
risk at specific intervals are shown below the Kaplan-Meier
curves and standard errors (SEs) of cumulative event rates
are provided.
Kaplan-Meier curves were compared primarily using
the log-rank test and multivariate analyses were performed
to adjust for predefined confounding factors using Cox
regression. A P value of .05 was considered to indicate
statistically significant differences. Generally, clinical out-
comes are reported separately for claudicants and CLI
patients.
RESULTS
During the study period, 98 patients (38 women, 104
limbs; mean age, 72  11 years) underwent endovascular
interventions for CFA obstructions (claudication, n  84
[81%]; CLI, n  20 [19%]). Demographic data and risk
factors are shown in Table I, whereas procedural details are
Table II. Procedural and angiographic details of 104 limb
artery obstructions
Total cohort (n 
Singular stenosis, n (%) 69 (66.3%)
Multifocal stenosis, n (%) 35 (33.7%)
Access site
Crossover, n (%) 80 (76.9)
Antegrade, n (%) 3 (2.9)
Retrograde, n (%) 16 (15.4)
Brachial, n (%) 5 (4.8)
CFA angioplasty 104
Mean diameter, mm (SD) 6.61 (1.21
Mean length, mm (SD) 30.63 (11.6
CFA stenting 28 (26.9%)
Balloon expandable 13 (12.5%)
Mean stent diameter, mm (SD) 7 (1)
Mean stent length, mm (SD) 16.8 (8.7)
Self-expandable 15 (14.4%) (53.
Mean diameter, mm ( SD) 7.27 (1.39
Mean length, mm (SD) 45 (22.2
Postprocedural angiographic findings
Crural run-off
0, n (%) 2
1, n (%) 25
2, n (%) 23
3, n (%) 54
Persistent SFA obstruction 30
Persistent deep femoral artery obstruction 4
CFA, Common femoral artery; CLI, critical limb ischemia; SD, standard deoutlined in Table II. pFifty cases (48%) presented with an inflow obstruction
ll of which could be treated with technical success. A
elevant outflow obstruction was found in 74 limbs, either
t the level of the superficial femoral artery (n  72; CLI,
3) and/or at the level of the deep femoral artery (n  13;
LI, 4). Endovascular outflow revascularization was at-
empted in 50/72 (69.4%) of cases with superficial femoral
rtery (SFA) (technical success rate: 84% [42/50]), and in
1 cases with deep femoral artery obstruction (technical
uccess rate: 82% [9/11]). Thus, a significant outflow
bstruction remained in 34 limbs (Table II). Treated le-
ions were classified as de novo in 88 (85%) and as recurrent
n 16 limbs (nine following endovascular, seven following
urgical revascularization). In the course of TER, revascu-
arization was performed in n 5 cases in the iliac and in n
6 cases in the femoropopliteal segment.
Balloon-expandable stents were deployed in 13 (13%),
hereas self-expandable stents were used in 15 cases (14%).
eri-interventional mortality was 0% and technical success
as achieved in all patients but one claudicant (1%) and one
LI patient (5%); both failures were due to a dissection of
he common femoral artery subsequent to balloon angio-
lasty. As a consequence, femoropopliteal bypass surgery
as performed. Of note, 24/28 of stent deployments were
onducted in 2003 or later, while angioplasty alone was
redominantly performed in earlier years.
Mean overall follow-up was 482 days (median 215
ays, interquartile range: 25th percentile  11 days, 75th
dergoing endovascular therapy for common femoral
CLI (n  20) Claudication (n  84) P value
10 (50%) 59 (70.2%) .1
10 (50%) 25 (29.8%) .1
16 (80.0) 64 (76.2) .5
1 (5.0) 2 (2.4) 1.0
2 (10.0) 14 (16.7) .6
1 (5.0) 4 (4.8) .4
20 84
6.15 (0.93) 6.71 (1.25) .2
32.3 (11.17) 30.24 (11.82) .8
8 (40%) 20 (23.8%) .2
2 (10%) 11 (13.1%) 1.0
7 (1.4) 7 (1) .9
27.5 (17.7) 14.9 (5.7) .06
6 (30%) (75%) 9 (45%) (10.7%) .06
6.83 (0.98) 7.55 (1.59) .3
43 (22.8) 46.3 (23.0) .8
1 (5%) 1 (1.2%) .4
7 (35%) 18 (21.4%) .2
5 (25%) 18 (21.4%) .8
7 (35%) 47 (56%) .1
10 (50%) 20 (23.8%) .03
0 (0%) 4 (4.8%) .7
; SFA, superficial femoral artery.s un
104)
)
7)
6%)
)
)ercentile  654 days).
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was 530 days (median 238 days, interquartile range: 25th
percentile  13 days, 75th percentile  716 days). Iatro-
genic CFA dissection occurred in n  1 case (1%) and
resolved without further sequelae after successful stent
placement. Primary sustained clinical improvement rates at
3, 6, 12, and 24 months were 81% (SE, 0.046), 75% (SE,
0.054), 68% (SE, 0.062), and 52% (SE, 0.08) (Fig 1),
whereas secondary sustained clinical improvement rates were
91% (SE, 0.034), 87% (SE, 0.042), 80% (SE, 0.056), and 68%
(SE,0.074) (Fig2), respectively.Clinical deterioration rateswere
3% at 3 months and 5% thereafter, whereas TLR and TER rates
amountedto8%(SE,0.033),12%(SE,0.043),17%(SE,0.052),
28% (SE, 0.078), and 5% (SE, 0.027), 19% (SE, 0.055), 24%
(SE, 0.061), and 28% (SE, 0.069) (Figs 3 and 4), respec-
tively.
ABI improved from 0.61  0.27 at baseline to 0.85 
0.24 postprocedurally (P  .001). Hemodynamic im-
Fig 1. Primary sustained clinical improvement in claudicants vs
critical limb ischemia (CLI). *Standard errors (SE) exceeding 10%.
Fig 2. Secondary sustained clinical improvement in claudicants vs
critical limb ischemia (CLI). *Standard errors (SE) exceeding 10%.provement was obtained in 37/42 cases (88.1%) of iliac mlus CFA revascularization, in 37/42 cases (88.1%) of CFA
lus femoropopliteal and below-the-knee revasculariza-
ion, and in 5/6 cases (83.3%) of CFA plus deep femoral
rtery revascularization, whereas it was found in 10/12
atients (83.3%) after isolated CFA revascularization.
Sustained hemodynamic improvement rates were 81%
SE, 0.046), 68% (SE, 0.061), 59% (SE, 0.066), and 35%
SE, 0.073) at assessed intervals. During follow-up, one
atient (1%) underwent a major amputation 50 months
ostprocedurally due to recurrent infections of the forefoot
espite stable arterial perfusion.
Clinical outcome in patients with CLI. Mean fol-
ow-up was 285 days (median 140 days, interquartile range:
5th percentile 11 days, 75th percentile 433 days). No
omplications have been reported. Primary sustained clini-
al improvement was 55.4% (SE, 0.120), 55.4% (SE,
.120), 39.6% (SE, 0.127), and 0% at 3, 6, 12, and 24
ig 3. Freedom of target lesion revascularization in claudicants vs
ritical limb ischemia (CLI). *Standard errors (SE) exceeding 10%.
ig 4. Freedom from target extremity revascularization in claudi-
ants vs critical limb ischemia (CLI). *Standard errors (SE) exceed-
ng 10%.onths (Fig 1). Secondary sustained clinical improvement
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April 20111004 Baumann et alrates were 77% (SE, 0.101) throughout (Fig 2). Clinical
deterioration rates were 0% out to 12 months. TLR rates
were 38% (SE, 0.121), 38% (SE, 0.121), 46% (SE, 0.133),
and 73% (SE, 0.201) at 3, 6, 12, and 24 months (Fig 3),
whereas TER rates were 26% (SE, 0.113), 26% (SE, 0.113),
35% (SE, 0.127), and 56% (SE, 0.197) (Fig 4).
ABI improved from 0.28  0.24 at baseline to 0.54 
0.20 postprocedurally (P  .001).
Hemodynamic improvement was obtained in 6/8 cases
(75%) of iliac plus CFA revascularization, in 7/8 cases
(87.5%) of CFA plus femoropopliteal and below-the-knee
revascularization, and in 3/5 cases (60%) of CFA plus deep
femoral artery revascularization, whereas it was found in
0/1 patients (0%) after isolated CFA revascularization.
Rates of sustained hemodynamic improvement were
43% (SE, 0.121), 36% (SE, 0.120), 27% (SE, 0.119), and
27% (SE, 0.119) at according intervals. Cumulative major
amputation rate was 6% at 24 months, whereas the minor
amputation rate was 13%. Cumulative mortality rates were
13% and 34% at 1 and 2 years, respectively.
Both primary sustained clinical and hemodynamic im-
provement rates were higher in claudicants compared with
CLI patients at 3, 6, 12, and 24 months (P  .007, by
log-rank test). Presence of persistent femoropopliteal out-
flow obstruction was associated with the need for TER in
univariate (P  .033, by log-rank) but not in multivariate
analysis.
In multivariate analysis adjusted for age, creatinine
levels, Rutherford stage at baseline, gender, coronary heart
disease, arterial hypertension, hypercholesterolemia, diabe-
tes mellitus, cerebrovascular insult, cigarette smoking, out-
flow obstruction at the level of the deep, and/or superficial
femoral artery and infrageniculate run-off, presence of isch-
emic skin lesions (hazard ratio [HR], 4.7; 95% confidence
interval [CI], 1.49-14.85; P  .009), persistent obstruc-
tion of the femoropopliteal tract at baseline (HR, 3.9; 95%
CI, 1.66-9.16; P  .002), and diabetes mellitus (HR, 2.3;
95% CI, 1.02-5.28; P  .005) were independently associ-
ated with impaired primary sustained clinical improvement.
Persistent outflow obstruction (HR, 5.7; 95% CI, 1.7-
18.5; P  .005), presence of ischemic ulcers (HR, 16.9;
95% CI, 3-93.5; P  .001), and diabetes mellitus (HR,
15.7; 95% CI, 1.4-173.6; P .03) were also independently
associated with higher TLR rates in this model. Conversely,
primary sustained clinical improvement was significantly
better in patients in whom stents had been implanted
subsequent to CFA angioplasty (HR, 0.24; 95% CI, 0.08-
0.73; P  .012).
DISCUSSION
While the role of endovascular therapy of the aortoiliac
segment5,21 and of the superficial femoral and popliteal
arteries22-24 has been studied extensively within recent
years, outcome data on surgical2,4,6 and endovascular re-
vascularization9-12,25,26 approaches for CFA obstructions
are limited to case reports9,10 and comparatively small-
sized clinical series.3,11,12,27 rBallotta et al reported clinical outcomes after surgical
FA revascularization within a prospective trial in 117
atients (n  121 limbs; CLI, 39.7%). Study endpoints
ncluded primary patency (PP), assisted primary patency
APP), limb salvage rate (LS), and mortality. PP and APP
ere not specifically defined, whereas LS was defined as no
mputation above the metatarsal level. Kang et al reported
retrospective series of 65 CFA endarterectomies (CLI,
2.3%), evaluating clinical assessment and technical success
ccording to the American Heart Association;28 reported
ndpoints were PP, APP, LS as well as mortality. A further
tudy performed by Kechagias et al retrospectively assessed
linical results of 111 isolated endarterectomies of the
emoral bifurcation in 90 consecutive patients (CLI,
0.6%). Endpoints analyzed included TER, LS, and mor-
ality. Of note, the definition of CLI varied substantially in
ontrast to the present series. Thereby, Kechagias and Kang
t al defined CLI only clinically, ie presence of rest pain,
lcers, or gangrene not further accounting for hemody-
amic criteria. In addition, none of the above-mentioned
tudies stratified outcomes for clinical presentation at base-
ine (claudication vs CLI).
Although endovascular treatment of CFA has first been
eported over 30 years ago,1,11,12 systematic studies assess-
ng its clinical utility are rare. Stricker and colleagues11
etrospectively analyzed 33 angioplasties with stent implan-
ation in 27 consecutive patients (CLI, 18%). Target sites
ncludedCFA (n 19), origins of SFA (n 2), or PFA (n 4)
s well as eight bypass anastomoses. Follow-up included assess-
ent of symptoms and clinical examination, ie, ABI measure-
entandduplexultrasound.Primarypatencyandhemodynamic
mprovement were endpoints of interest. In that series, statistical
nalysis did not account for the influence of confounding risk
actors, and results were not stratified for clinical presentation at
aseline.Moreover, Johnston et al12 prospectively assessed clini-
al outcomes of 18 patients undergoing endovascular CFA ther-
py. However, analysis of these patients was only within the
rameworkof a larger-scale studyexamining theoutcomeofPTA
n a total of 902 PAD patients, thereby not specifically elaborat-
ng on outcomes after CFA angioplasty. Silva et al3 retrospec-
ively analyzed 21 limbs in 20 patients with symptomatic lower
imb ischemia. Endpoints were focused on the analysis of clinical
mprovement, defined as an improvement of at least one func-
ional class according to Fontaine, and event-free survival.
Technical success rates were reported to be as high as
00% after surgical repair4,6 and ranged from 91%3 to
00%11 after endovascular CFA therapy. The 98% technical
uccess rate in the present series confirms earlier endovas-
ular data showing that similar technical outcomes can be
chieved using both methods.
Perioperative minor complications after CFA surgery
ere reported to occur in 6.6%4 to 17.7%7 of cases. Major
omplications subsequent to surgical CFA revasculariza-
ion requiring surgical reintervention were reported to
ange from 0%4 up to 1.8%.7 In contrast, endovascular
tudies reported minor complications in up to 9.5%,2,3,11,12
hereas major complications, ie, large hematomas, hemor-
hagic shock, or ischemia occurred in up to 3.4%.2,3,11,12
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reflecting downsizing of endovascular devices and in-
creased experiences with endovascular techniques.11
Ballotta and Kang reported clinical improvement in
99% to 100% of cases.4,6 Both studies, however, reported
only postprocedural clinical outcomes and no stratification
for clinical presentation at baseline was performed. More-
over, Silva and coworkers observed sustained clinical im-
provement in 81%3 after a mean of 34 months. Stricker did
not report further functional clinical outcome parameters
beyond the published 1-year patency rate of 87%11 and a
significant mean sustained hemodynamic improvement at
the last observation. In our series, primary sustained clinical
improvement at 12 months was achieved in 68.3% of
claudicants and 39.6% of CLI, while it was substantially
higher if reinterventions were performed. Our compara-
tively strict definitions of both CLI15 and primary sustained
clinical improvement16 might explain the seemingly poor
treatment results compared with other series.
TLR as an expression of target lesion failure was re-
ported to range from 1.7% at 47 months4 to 7.7% after 17
months6 after surgical CFA revascularization. Moreover, it
was reported to be 10% after 11 months.3 In contrast, our
results indicate 2-year TLR rates of 28.3% in claudicants
and 73.2% in CLI patients, respectively. Moreover, TER as
an expression of progression of obstructive lesions outside
the initially treated target lesion were reported to be as high
as 22% at 5 years 6 and 36.9% at 15 years after surgical CFA
treatment.7 In the present series, the TER rate was 27% in
claudicants and 56% in CLI patients after 2 years, indicating
that progression of atherothrombosis contributes similarly
to the need for repeated revascularization as does the
phenomenon of restenosis.
Hemodynamic improvement is an important outcome
measure after both surgical and endovascular CFA revascu-
larization. Surgical series reported hemodynamic success in
at least 95%6 up to 100%,4 whereas the hemodynamic
improvement rate was 82% in the present series in which
multilevel disease was observed in a majority of cases.
Further endovascular studies presented immediate hemo-
dynamic improvement in up to 100%.11 Thus, ABI im-
provement can be achieved, regardless of revascularization
modality.
Amputation rates after surgical CFA therapy were re-
ported to range from 0% after 5 years6 to 14.8% after 15
years.7 However, outcomes were not stratified for clinical
presentation at baseline in these studies. Endovascular
studies reported below-the-knee amputation rates as low as
3%,11 whereas major amputation became necessary in 6.3%
of CLI patients at 24 months. However, the need for
amputation depends on clinical and angiographic presenta-
tion of the target limb at baseline and on concomitant
therapy such as antibiotics and offloading, rather than on
CFA patency subsequent to revascularization alone.
Perioperative mortality was reported to range from 0%
to 2.8%4,7,29 after surgical CFA revascularization, whereas
it was reported to be 0%3,11 in two earlier endovascular
series as well as in the present study. Depending on patient caseline characteristics, long-term mortality was reported
n 20% at 5 years4 and in 82.4% at 15 years6 postoperatively.
ccordingly, 4-year mortality rates were reported to be
8.2%,11 while it was 34.4% in CLI patients within the
resent series. Given the comparatively low rates of periop-
rative mortality after both surgical and endovascular CFA
evascularization, it is likely that patient comorbidities
ather than the choice of the procedure independently
mpact on long-term mortality.
Most surgical studies reported arterial patency rates
anging from 93%6 up to 96%4 after 5 and 7 years, respec-
ively. Only one endovascular CFA revascularization study
eported patency, which was 83% at 3 years.11
In the present series, presence of ischemic ulcers at
aseline was identified as a predictor of lower primary
ustained clinical improvement and increased need for
LR. This is in line with earlier observations26 and reflects
he impact of initial clinical presentation on treatment
utcomes. Moreover, presence of diabetes mellitus was
ssociated with lower primary sustained clinical improve-
ent and higher TLR rates. This observation is not new13
nd has also been observed after surgical CFA revascular-
zation.4 Furthermore, the use of stents was associated with
mproved primary sustained clinical improvement. This
nding might explain that, in contrast to the superficial
emoral and popliteal artery, the common femoral artery
ight behave more like an elastic artery such as the iliac
rteries and respond better to stent placement. During the
ourse of the study period, the application policies of stents
t the level of the CFA have changed shifting toward the use
f self-expandable stents.
Our study has several limitations. First, it has a nonran-
omized design and a purely observational character due to
ost hoc analysis. Second, the lack of systematically col-
ected information on arterial patency as determined by
uplex sonography or angiography precludes important
nformation. Third, the absence of a surgical control group
oes not allow for a direct comparison of both revascular-
zation methods.
In summary, results of the above-mentioned surgical
nd endovascular CFA revascularization studies present a
ide range of results, mainly attributable to both the
eterogeneity of study endpoints utilized3,4,6,7,11 and
he diversity of patient populations4,12 studied. Thus,
ppraisal of these studies is very difficult and only a
andomized trial comparing surgical to endovascular
FA revascularization could answer some of the impend-
ng questions.
In conclusion, endovascular therapy of CFA obstruc-
ions is a promising minimally invasive treatment option for
atients with patent femoropopliteal outflow. Further pro-
pective investigations utilizing uniform endpoint defini-
ions are required. In the absence of a direct randomized
omparison, endovascular and surgical revascularization
pproaches should be regarded complementary but not
ompeting treatment approaches.
11
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2
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